The role of monoclonal antibodies in the treatment of severe asthma

Therapeutic Advances in Respiratory Disease

Volumn 5, Issue 3, 2011, Pages 183-194

  Tourangeau, Louanne M ^a   Kavanaugh, Arthur ^a,b   Wasserman, Stephen I ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Allergy and Rheumatology Center   (United States)

Author keywords

asthma management; monoclonal antibodies; severe asthma

Indexed keywords

ADALIMUMAB; ALLERGEN; AMG 317; BENRALIZUMAB; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHROMONE DERIVATIVE; CORTICOSTEROID; CREATINE KINASE; DACLIZUMAB; ENOKIZUMAB; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN E; INFLIXIMAB; KELIXIMAB; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LUMILIXIMAB; MEPOLIZUMAB; MONOCLONAL ANTIBODY; OMALIZUMAB; PASCOLIZUMAB; PLACEBO; RESLIZUMAB; STEROID; THEOPHYLLINE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ALLERGIC ASTHMA; ANAPHYLAXIS; ANTIBODY PRODUCTION; ANTIBODY STRUCTURE; ASTHMA; BIOLOGICAL THERAPY; BREAST CANCER; CD4 LYMPHOCYTE COUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHURG STRAUSS SYNDROME; CREATINE KINASE BLOOD LEVEL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG INFUSION REACTION; EOSINOPHILIA; HEART FAILURE; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INFECTION; LEUKOCYTE COUNT; LUNG SARCOIDOSIS; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; OPPORTUNISTIC INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIRUS MENINGITIS;

AIRWAY REMODELING; ANIMALS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; DRUG DESIGN; HUMANS; INFLAMMATION; SEVERITY OF ILLNESS INDEX;

EID: 79957864313     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465811400489     Document Type: Review

References (58)

1. Aaronson D.W. (2006) The “black box” warning and allergy drugs. J Allergy Clin Immunol 117: 40–44.
2. Abbas A. (2010) Cellular and Molecular Immunology, 6th edition, Saunders/Elsevier: Philadelphia.
3. Berry M.A. Hargadon B. Shelley M. Parker D. Shaw D.E. Green R.H. (2006) Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 354: 697–708.
4. Boulet L.P. Chapman K.R. Cote J. Kalra S. Bhagat R. Swystun V.A. (1997) Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 155: 1835–1840.
5. Bousquet J. Cabrera P. Berkman N. Buhl R. Holgate S. Wenzel S. (2005) The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 60: 302–308.
6. Brightbill H.D. Jeet S. Lin Z. Yan D. Zhou M. Tan M. (2010) Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. J Clin Invest 120: 2218–2229.
7. Brightling C. Berry M. Amrani Y. (2008) Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol 121: 5–10, quiz 11-12.
8. Busse W. Corren J. Lanier B.Q. McAlary M. Fowler-Taylor A. Cioppa G.D. (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108: 184–190.
9. Busse W.W. Israel E. Nelson H.S. Baker J.W. Charous B.L. Young D.Y. (2008) Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med 178: 1002–1008.
10. Busse W.W. Katial R. Gossage D. Sari S. Wang B. Kolbeck R. (2010) Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 125: 1237–1244 e1232.
11. Casale T.B. Bernstein I.L. Busse W.W. LaForce C.F. Tinkelman D.G. Stoltz R.R. (1997) Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 100: 110–121.
12. Chang T.W. (2000) The pharmacological basis of anti-IgE therapy. Nat Biotechnol 18: 157–162.
13. Corren J. Busse W. Meltzer E.O. Mansfield L. Bensch G. Fahrenholz J. (2010) A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 181: 788–796.
14. Cruz A.A. Lima F. Sarinho E. Ayre G. Martin C. Fox H. (2007) Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy 37: 197–207.
15. Depper J.M. Leonard W.J. Robb R.J. Waldmann T.A. Greene W.C. (1983) Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. J Immunol 131: 690–696.
16. Doherty T. Broide D. (2007) Cytokines and growth factors in airway remodeling in asthma. Curr Opin Immunol 19: 676–680.
17. Erin E.M. Leaker B.R. Nicholson G.C. Tan A.J. Green L.M. Neighbour H. (2006) The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 174: 753–762.
18. Erzurum S.C. (2006) Inhibition of tumor necrosis factor alpha for refractory asthma. N Engl J Med 354: 754–758.
19. Flood-Page P. Menzies-Gow A. Phipps S. Ying S. Wangoo A. Ludwig M.S. (2003) Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112: 1029–1036.
20. Flood-Page P. Swenson C. Faiferman I. Matthews J. Williams M. Brannick L. (2007) A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 176: 1062–1071.
21. Genentech (2003) Omalizumab prescribing information, South San Francisco, CA: Genentech, Inc.
22. Gruenberg D. Busse W. (2010) Biologic therapies for asthma. Curr Opin Pulm Med 16: 19–24.
23. Haldar P. Brightling C.E. Hargadon B. Gupta S. Monteiro W. Sousa A. (2009) Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360: 973–984.
24. Hansel T.T. Kropshofer H. Singer T. Mitchell J.A. George A.J. (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9: 325–338.
25. Hart T.K. Blackburn M.N. Brigham-Burke M. Dede K. Al-Mahdi N. Zia-Amirhosseini P. (2002) Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 130: 93–100.
26. Hochhaus G. Brookman L. Fox H. Johnson C. Matthews J. Ren S. (2003) Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 19: 491–498.
27. Howarth P.H. Babu K.S. Arshad H.S. Lau L. Buckley M. McConnell W. (2005) Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60: 1012–1018.
28. Humbert M. Beasley R. Ayres J. Slavin R. Hebert J. Bousquet J. (2005) Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60: 309–316.
29. Junghans R.P. Waldmann T.A. Landolfi N.F. Avdalovic N.M. Schneider W.P. Queen C. (1990) Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 50: 1495–1502.
30. Kips J.C. O'Connor B.J. Langley S.J. Woodcock A. Kerstjens H.A. Postma D.S. (2003) Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 167: 1655–1659.
31. Koike M. Nakamura K. Furuya A. Iida A. Anazawa H. Takatsu K. (2009) Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity. Hum Antibodies 18: 17–27.
32. Kolbeck R. Kozhich A. Koike M. Peng L. Andersson C.K. Damschroder M.M. (2010) MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 125: 1344–1353 e1342.
33. Kon O.M. Sihra B.S. Compton C.H. Leonard T.B. Kay A.B. Barnes N.C. (1998) Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 352: 1109–1113.
34. Korn S. Thielen A. Seyfried S. Taube C. Kornmann O. Buhl R. (2009) Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 103: 1725–1731.
35. Leckie M.J. ten Brinke A. Khan J. Diamant Z. O'Connor B.J. Walls C.M. (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356: 2144–2148.
36. Lee S.J. Chinen J. Kavanaugh A. (2010) Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines, and immunoglobulins. J Allergy Clin Immunol 125(2 Suppl.2): S314's323.
37. Limb S.L. Starke P.R. Lee C.E. Chowdhury B.A. (2007) Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 120: 1378–1381.
38. Lin H. Boesel K.M. Griffith D.T. Prussin C. Foster B. Romero F.A. (2004) Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 113: 297–302.
39. Long A.A. (2009a) Immunomodulators in the treatment of asthma. Allergy Asthma Proc 30: 109–119.
40. Long A.A. (2009b) Monoclonal antibodies and other biologic agents in the treatment of asthma. MAbs 1: 237–246.
41. Martin-Mateos M. (2007) Monoclonal antibodies in Pediatrics: use in prevention and treatment. Allergologia Immunopathologia 35: 145–150.
42. McDyer J.F. Li Z. John S. Yu X. Wu C.Y. Ragheb J.A. (2002) IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-gamma production. J Immunol 169: 2736–2746.
43. Miki-Hosokawa T. Hasegawa A. Iwamura C. Shinoda K. Tofukuji S. Watanabe Y. (2009) CD69 controls the pathogenesis of allergic airway inflammation. J Immunol 183: 8203–8215.
44. Milgrom H. Fick R.B. Jr Su J.Q. Reimann J.D. Bush R.K. Watrous M.L. (1999) Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 341: 1966–1973.
45. Morjaria J.B. Chauhan A.J. Babu K.S. Polosa R. Davies D.E. Holgate S.T. (2008) The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax 63: 584–591.
46. Nair P. Pizzichini M.M. Kjarsgaard M. Inman M.D. Efthimiadis A. Pizzichini E. (2009) Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360: 985–993.
47. Pauwels R.A. Brusselle G.G. Tournoy K.G. Lambrecht B.N. Kips J.C. (1998) Cytokines and their receptors as therapeutic targets in asthma. Clin Exp Allergy 28(Suppl. 3): 1–5.
48. Poole J.A. Meng J. Reff M. Spellman M.C. Rosenwasser L.J. (2005) Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol 116: 780–788.
49. Prussin C. Griffith D.T. Boesel K.M. Lin H. Foster B. Casale T.B. (2003) Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 112: 1147–1154.
50. Queen C. Schneider W.P. Selick H.E. Payne P.W. Landolfi N.F. Duncan J.F. (1989) A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 86: 10029–10033.
51. Ricci M. (1994) IL-4: a key cytokine in atopy. Clin Exp Allergy 24: 801–812.
52. Saini S.S. MacGlashan D.W. Jr Sterbinsky S.A. Togias A. Adelman D.C. Lichtenstein L.M. (1999) Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 162: 5624–5630.
53. Shames R.S. Vexler V. Lane N.M. McClellan M. Shi J. Keller S. (2001) The safety and pharmacokinetics of SB240683 anti-Il-4 humanized monoclonal antibody) in patients with mild to moderate asthma. J Allergy Clin Immunol 107: S316's316.
54. Singh J. Kraft M. (2008) Anti-IgE and other antibody targets in asthma. Handb Exp Pharmacol 181: 257–288.
55. Soler M. Matz J. Townley R. Buhl R. O'Brien J. Fox H. (2001) The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18: 254–261.
56. Waldmann T.A. Goldman C.K. Robb R.J. Depper J.M. Leonard W.J. Sharrow S.O. (1984) Expression of interleukin 2 receptors on activated human B cells. J Exp Med 160: 1450–1466.
57. Weiner L.M. Surana R. Wang S. (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10: 317–327.
58. Wenzel S.E. Barnes P.J. Bleecker E.R. Bousquet J. Busse W. Dahlen S.E. (2009) A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 179: 549–558.